'A done deal': FDA ad­vi­so­ry com­mit­tee votes unan­i­mous­ly against ef­fi­ca­cy da­ta for OTC nasal de­con­ges­tant

Mem­bers of an FDA ad­vi­so­ry com­mit­tee on Tues­day vot­ed unan­i­mous­ly against the ef­fi­ca­cy of an over-the-counter nasal de­con­ges­tant that’s been on the US mar­ket for more than 75 years.

The FDA called up­on the Non­pre­scrip­tion Drugs Ad­vi­so­ry Com­mit­tee to weigh in on new da­ta on oral phenyle­phrine, an in­gre­di­ent in pop­u­lar prod­ucts such as Mucinex and Be­nadryl. Mem­bers vot­ed 16-0 that da­ta sug­gest the med­ica­tion is not ef­fec­tive at the cur­rent­ly rec­om­mend­ed 10 mg dose for nasal de­con­ges­tion, and a ma­jor­i­ty agreed that they aren’t like­ly to be swayed by fur­ther re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA